{"ATC Code":"B - Blood and blood forming organs","Abbreviation":"Gly","Aliases":["Glycocoll","Glycolixir","Glicoamin","Glycosthene","Aciport","Padil","Hampshire glycine","Amitone","Leimzucker","Aminoazijnzuur"],"CAS":"56-40-6","ChEBI":"CHEBI:15428","ChEMBL":"CHEMBL773","ChemicalClasses":["alcohol"],"Chirality":"achiral","Classes":null,"Color/Form":"White crystals","Decomposition":"STARTS TO DECOMP AT 233 °C","Density":"1.1607 (NTP, 1992) - Denser than water; will sink g/cm\u003csup\u003e3\u003c/sup\u003e","Dosing Info":[],"Drug Indication":"Supplemental glycine may have antispastic activity. Very early findings suggest it may also have antipsychotic activity as well as antioxidant and anti-inflammatory activities.","DrugClasses":["antipsychotic","hormone"],"EINECS":"200-272-2","Esters":["acetate","benzoate"],"European Community (EC) Number":"200-272-2","FullSalts":["Glycine hydrochloride","Glycine hydriodide"],"HMDB ID":"HMDB0000123","HeavyAtomCount":5,"Human Drugs":"Human drug -\u003e Prescription","IUPACName":"2-aminoacetic acid","Impurities":["methenamine","triglycine","chloroacetic acid","diglycine","2,5-piperazinedione","iminodiacetic acid"],"InChI":"InChI=1S/C2H5NO2/c3-1-2(4)5/h1,3H2,(H,4,5)","InChIKey":"DHMQDGOQFOQNFH-UHFFFAOYSA-N","MeSH Pharmacological Classification":"Substances used for their pharmacological actions on glycinergic systems. Glycinergic agents include agonists, antagonists, degradation or uptake inhibitors, depleters, precursors, and modulators of receptor function. (See all compounds classified as Glycine Agents.)","Melting Point":"451 °","MolecularFormula":"C\u003csub\u003e2\u003c/sub\u003eH\u003csub\u003e5\u003c/sub\u003eNO\u003csub\u003e2\u003c/sub\u003e","MolecularWeight":"75.07 g/mol","Odor":"Odorless","Pharmacodynamics":"Helps trigger the release of oxygen to the energy requiring cell-making process; Important in the manufacturing of hormones responsible for a strong immune system.","Physical Description":"Glycine appears as white crystals. (NTP, 1992)","PrevSalts":["hydrochloride","hydriodide"],"PubChemId":750,"Record Description":["Glycine appears as white crystals. (NTP, 1992)","Glycine is the simplest (and the only achiral) proteinogenic amino acid, with a hydrogen atom as its side chain. It has a role as a nutraceutical, a hepatoprotective agent, an EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor, a NMDA receptor agonist, a micronutrient, a fundamental metabolite and a neurotransmitter. It is an alpha-amino acid, a serine family amino acid and a proteinogenic amino acid. It is a conjugate base of a glycinium. It is a conjugate acid of a glycinate. It is a tautomer of a glycine zwitterion.","A non-essential amino acid. It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter.","Glycine is a metabolite found in or produced by Escherichia coli (strain K12, MG1655).","Glycine has been reported in Microchloropsis, Pinus densiflora, and other organisms with data available.","Glycine is a non-essential, non-polar, non-optical, glucogenic amino acid. Glycine, an inhibitory neurotransmitter in the CNS, triggers chloride ion influx via ionotropic receptors, thereby creating an inhibitory post-synaptic potential. In contrast, this agent also acts as a co-agonist, along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors. Glycine is an important component and precursor for many macromolecules in the cells.","GLYCINE is a small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 12 investigational indications.","Glycine is a simple, nonessential amino acid, although experimental animals show reduced growth on low-glycine diets. The average adult ingests 3 to 5 grams of glycine daily. Glycine is involved in the body's production of DNA, phospholipids and collagen, and in release of energy. Glycine levels are effectively measured in plasma in both normal patients and those with inborn errors of glycine metabolism. Nonketotic hyperglycinaemia (OMIM 606899) is an autosomal recessive condition caused by deficient enzyme activity of the glycine cleavage enzyme system (EC 2.1.1.10). The glycine cleavage enzyme system comprises four proteins: P-, T-, H- and L-proteins (EC 1.4.4.2, EC 2.1.2.10 and EC 1.8.1.4 for P-, T- and L-proteins). Mutations have been described in the GLDC (OMIM 238300), AMT (OMIM 238310), and GCSH (OMIM 238330) genes encoding the P-, T-, and H-proteins respectively. The glycine cleavage system catalyses the oxidative conversion of glycine into carbon dioxide and ammonia, with the remaining one-carbon unit transferred to folate as methylenetetrahydrofolate. It is the main catabolic pathway for glycine and it also contributes to one-carbon metabolism. Patients with a deficiency of this enzyme system have increased glycine in plasma, urine and cerebrospinal fluid (CSF) with an increased CSF: plasma glycine ratio.  (A3412). t is also a fast inhibitory neurotransmitter.","A non-essential amino acid. It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter.","See also: Glycine Hydrochloride (has salt form); Amlisimod (monomer of); ProSol (FDA NDC: 0338-0499) (component of) ... View More ...","Glycine is the simplest (and the only achiral) proteinogenic amino acid, with a hydrogen atom as its side chain. It has a role as a nutraceutical, a hepatoprotective agent, an EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor, a NMDA receptor agonist, a micronutrient, a fundamental metabolite and a neurotransmitter. It is an alpha-amino acid, a serine family amino acid and a proteinogenic amino acid. It is a conjugate base of a glycinium. It is a conjugate acid of a glycinate. It is a tautomer of a glycine zwitterion."],"References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Glycine","Name":"Glycine","Sub":false}]},{"Name":"Wikidata","Urls":[{"Link":"https://www.wikidata.org/wiki/Q106345678","Name":"Glycine","Sub":false}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/drugs/DB00145","Name":"Glycine","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/750","Name":"Glycine","Sub":false}]},{"Name":"ChEMBL","Urls":[{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL773","Name":"Glycine","Sub":false}]},{"Name":"ChEBI","Urls":[{"Link":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:15428","Name":"Glycine","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=56-40-6","Name":"Glycine","Sub":false}]},{"Name":"HMDB","Urls":[{"Link":"https://hmdb.ca/metabolites/HMDB0000123","Name":"Glycine","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/C00037","Name":"Glycine","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/TE7660XO1C","Name":"Glycine","Sub":false}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID9020667","Name":"Glycine","Sub":false}]}],"SMILES":"C(C(=O)O)N","Salts":["hydrochloride","hydriodide"],"SaltsAcidCount":[1,0],"SaltsAmineCount":[1,2],"SaltsUNII":["225ZLC74HX","J56052844H"],"Solubility":"greater than or equal to 100 mg/mL at 64 °F (NTP, 1992)","Stereoisomers":["(-)-Glycine"],"StereoisomersUNII":[""],"StoreUNII":["TE7660XO1C"],"StructureBase64":"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","Taste":"Sweet","Therapeutic Uses":"AMINOACETIC ACID HAS BEEN OCCASIONALLY USED IN THERAPY OF MYASTHENIA GRAVIS BUT MOST INVESTIGATORS DOUBT THAT THE CMPD HAS ANY VALUE IN THIS DISORDER. ... /IT/ IS ALSO USED IN...ANTACID PREPN, SOMETIMES AS A COMPLEX SALT. HOWEVER.../IT HAS/ LIMITED BUFFERING CAPACITY...","Title":"Glycine","UNII":"TE7660XO1C","Wikidata":"Q106345678","Wikipedia":"Glycine","XLogP":-3.2,"pH":"0.2 molar soln in water: 4.0"}